미국의 말초혈관용 액체 색전제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2036년)

U.S. Peripheral Liquid Embolic Agents Market Summary

The U.S. peripheral liquid embolic agents market size was valued at USD 99.7 million in 2025 and is projected to grow from USD 110.3 million in 2026 to USD 222.7 million by 2036, at a CAGR of 7.3% from 2026 to 2036. The rising prevalence of peripheral artery disease (PAD) and other vascular disorders in the U.S. is increasing demand for vascular interventions.

In addition, minimally invasive endovascular procedures are gaining adoption due to reduced surgical trauma, shorter hospital stays, and faster recovery. The growing availability of interventional radiology services and advanced catheter-based techniques is further supporting the use of liquid embolic agents in peripheral vascular procedures. The growing cancer burden in the U.S. is increasing the number of patients requiring peripheral vascular embolization for the management of hypervascular tumors, particularly in interventional oncology. Procedures such as transarterial embolization (TAE) and transarterial chemoembolization (TACE) selectively occlude tumor-feeding vessels, creating a demand for embolic technologies capable of controlled, targeted vessel occlusion.

Liquid embolic agents are particularly relevant because they can penetrate distal and complex vascular networks and form an occlusive cast within the targeted vessels. The increasing use of image-guided embolization for liver and other hypervascular tumors, together with advances in microcatheter delivery and embolic technology, is expanding the range of applications for peripheral liquid embolics. In the U.S., embolization therapies accounted for a substantial share of the interventional oncology procedures market, with liver cancer the largest cancer-type segment in 2025. According to the American Cancer Society, 42,240 new cases of primary liver and intrahepatic bile duct cancer were expected in the U.S. in 2025, with approximately 30,090 deaths, highlighting the substantial patient population requiring effective treatment options, including transarterial embolization.

U.S. Peripheral Liquid Embolic Agents Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2036. For this study, Grand View Research has segmented the U.S. peripheral liquid embolic agents market report based on product, application, and end-use:

• Product Outlook (Revenue, USD Million, 2021 - 2036)
  • Ethylene Vinyl Alcohol Copolymer (EVOH)
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2036)
  • Peripheral Vascular Hemorrhage
  • Hypervascular Tumors
  • Peripheral Vascular Malformations / AVMs
  • Aneurysms / Pseudoaneurysms
  • Type II Endoleaks
  • Portal Vein Embolization (PVE)
  • Venous Applications (varicocele, PCS, varicose veins)
  • Other Peripheral Embolization Applications
• End-use Outlook (Revenue, USD Million, 2021 - 2036)
  • Hospitals & Interventional Radiology (IR) Suites
  • Ambulatory Surgical Centers (ASCs)
  • Specialty Clinics / Vascular Centers
  • Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Product
  • 1.1.2. Application
  • 1.1.3. End Use
  • 1.1.4. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Peripheral Liquid Embolic Agents Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising prevalence of peripheral artery disease and other vascular disorders in the U.S.
    • 3.2.1.2. Increasing adoption of minimally invasive endovascular embolization procedures
    • 3.2.1.3. Increasing cancer burden in the country driving interventional oncology
    • 3.2.1.4. Continuous innovation in liquid embolic technologies
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of liquid embolic agents and associated procedure costs
    • 3.2.2.2. Limited reimbursement for selected peripheral embolization procedures
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Expansion of peripheral embolization applications beyond oncology
    • 3.2.3.2. Increasing adoption of embolization in trauma and emergency hemorrhage management
    • 3.2.3.3. Growth in outpatient embolization across ambulatory surgical centers
    • 3.2.3.4. Development of AI-guided and image-guided embolization technologies
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Risk of non-target embolization and procedure-related complications
    • 3.2.4.2. Shortage of skilled interventional radiologists and endovascular specialists
• 3.3. U.S. Peripheral Liquid Embolic Agents Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. U.S. Peripheral Liquid Embolic Agents Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Peripheral Liquid Embolic Agents Market: Product Movement Analysis, 2025 & 2036 (USD Million)
• 4.3. U.S. Peripheral Liquid Embolic Agents Market Size & Trend Analysis, by Product, 2021 to 2036 (USD Million)
• 4.4. Ethylene Vinyl Alcohol Copolymer (EVOH)
  • 4.4.1. Ethylene Vinyl Alcohol Copolymer (EVOH) market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 4.5. Other Embolic Agents
  • 4.5.1. Other Embolic Agents market revenue estimates and forecasts, 2021 - 2036 (USD Million)

Chapter 5. U.S. Peripheral Liquid Embolic Agents Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Peripheral Liquid Embolic Agents Market: Application Movement Analysis, 2025 & 2036 (USD Million)
• 5.3. U.S. Peripheral Liquid Embolic Agents Market Size & Trend Analysis, by Application 2021 to 2036 (USD Million)
• 5.4. Peripheral Vascular Hemorrhage
  • 5.4.1. Peripheral Vascular Hemorrhage market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 5.5. Hypervascular Tumors
  • 5.5.1. Hypervascular Tumors market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 5.6. Peripheral Vascular Malformations / AVMs
  • 5.6.1. Peripheral Vascular Malformations/AVMs market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 5.7. Aneurysms / Pseudoaneurysms
  • 5.7.1. Aneurysms / Pseudoaneurysms market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 5.8. Type II Endoleaks
  • 5.8.1. Type II Endoleaks market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 5.9. Portal Vein Embolization (PVE)
  • 5.9.1. Portal Vein Embolization (PVE)market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 5.10. Venous Applications (varicocele, PCS, varicose veins)
  • 5.10.1. Venous Applications (varicocele, PCS, varicose veins) market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 5.11. Other Peripheral Embolization Applications
  • 5.11.1. Other Peripheral Embolization Applications market revenue estimates and forecasts, 2021 - 2036 (USD Million)

Chapter 6. U.S. Peripheral Liquid Embolic Agents Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global U.S. Peripheral Liquid Embolic Agents Market: End Use Movement Analysis, 2025 & 2036 (USD Million)
• 6.3. Global U.S. Peripheral Liquid Embolic Agents Market Size & Trend Analysis, by End Use, 2021 to 2036 (USD Million)
• 6.4. Hospitals & Interventional Radiology (IR) Suites
  • 6.4.1. Hospitals & Interventional Radiology (IR) Suites market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 6.5. Ambulatory Surgical Centers (ASCs)
  • 6.5.1. Ambulatory Surgical Centers (ASCs) market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 6.6. Specialty Clinics / Vascular Centers
  • 6.6.1. Specialty Clinics / Vascular Centers market revenue estimates and forecasts, 2021 - 2036 (USD Million)
• 6.7. Others
  • 6.7.1. Others market revenue estimates and forecasts, 2021 - 2036 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Market Share Analysis, 2025
• 7.4. Company Heat Map Analysis
• 7.5. Strategy Mapping
  • 7.5.1. Expansion
  • 7.5.2. Mergers & Acquisition
  • 7.5.3. Partnerships & Collaborations
  • 7.5.4. New Technology Launches
  • 7.5.5. Research And Development
  • 7.5.6. Company Profiles
  • 7.5.7. Boston Scientific Corporation
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Terumo Medical Corporation (MicroVention)
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. BlackSwan Vascular (Sirtex Medical)
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Instylla, Inc.
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic initiatives